Suppr超能文献

注射组织型纤溶酶原激活剂和气体治疗年龄相关性黄斑变性继发的黄斑下出血后发生的孔源性视网膜脱离

RHEGMATOGENOUS RETINAL DETACHMENT AFTER INJECTION OF TISSUE PLASMINOGEN ACTIVATOR AND GAS FOR SUBMACULAR HEMORRHAGE SECONDARY TO AGE-RELATED MACULAR DEGENERATION.

作者信息

Manrique-Lipa Roslyn, Jasim Haneen, Safi Antoine, Liyanage Sidath E, Keller Johannes

机构信息

Bristol Eye Hospital, University Hospitals Bristol and Weston NHS Foundation Trust, Lower Maudlin Street, Bristol, United Kingdom.

出版信息

Retin Cases Brief Rep. 2024 Jan 1;18(1):131-134. doi: 10.1097/ICB.0000000000001333.

Abstract

PURPOSE

The purpose of this study was to describe the rate, clinical characteristics, and outcomes of rhegmatogenous retinal detachment (RRD) after injection of tissue plasminogen activator (TPA) and gas for submacular hemorrhage displacement.

METHODS

Retrospective analysis of consecutive cases developing RRD after TPA injection and gas for submacular hemorrhage displacement. The rate of RRD was calculated, and a description of RRD clinical characteristics was performed. Anatomic and visual outcomes after RRD repair were analyzed.

RESULTS

Ninety eyes of 90 patients were analyzed. Tissue plasminogen activator was given intravitreally in 53 eyes (59%) and subretinally in 37 eyes (41%). RRD occurred in 6 of 90 eyes (7%). Of these, one had intravitreal TPA and five had vitrectomy with subretinal TPA ( P = 0.04). The mean age was 75 (64-93) years. The median time of RRD occurrence was 42 (1-134) days. All cases had macular involvement. Two cases had PVR at presentation. Vitrectomy was performed in all cases and silicone oil used in five, all of which resulted in permanent silicone oil retention. One case (17%) achieved primary single surgery success. The median final visual acuity was 1.8 logMAR (20/1,260 Snellen).

CONCLUSION

The RRD rate after submacular hemorrhage displacement was 7% in our case series. Rhegmatogenous retinal detachment occurred more commonly after vitrectomy with subretinal TPA injection. The visual and anatomic outcomes were poor, with a high rate of retained silicone oil and recurrent RRD.

摘要

目的

本研究旨在描述玻璃体腔内注射组织型纤溶酶原激活剂(TPA)联合气体用于黄斑下出血移位后孔源性视网膜脱离(RRD)的发生率、临床特征及预后。

方法

对连续发生的玻璃体腔内注射TPA联合气体用于黄斑下出血移位后发生RRD的病例进行回顾性分析。计算RRD的发生率,并对RRD的临床特征进行描述。分析RRD修复术后的解剖和视力预后。

结果

分析了90例患者的90只眼。53只眼(59%)行玻璃体腔内注射TPA,37只眼(41%)行视网膜下注射TPA。90只眼中6只眼(7%)发生RRD。其中,1只眼行玻璃体腔内注射TPA,5只眼行玻璃体切除联合视网膜下注射TPA(P = 0.04)。平均年龄为75(64 - 93)岁。RRD发生的中位时间为42(1 - 134)天。所有病例均累及黄斑。2例初诊时存在增殖性玻璃体视网膜病变(PVR)。所有病例均行玻璃体切除术,5例行硅油填充,所有病例均导致永久性硅油存留。1例(17%)首次手术成功。最终视力中位数为1.8 logMAR(20/1260 Snellen)。

结论

在我们的病例系列中,黄斑下出血移位后RRD的发生率为7%。视网膜下注射TPA联合玻璃体切除术后孔源性视网膜脱离更常见。视力和解剖学预后较差,硅油存留率高且RRD复发率高。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验